演題抄録

臓器別シンポジウム

開催概要
開催回
第58回・2020年・京都
 

進行性去勢感受性前立腺癌の治療戦略 :ドセタキセル

演題番号 : SY8-3

[筆頭演者]
小坂 威雄:1 
[共同演者]
大家 基嗣:1

1:慶應義塾大学・泌尿器科

 

Docetaxel has been positioned as the standard treatment overseas because of its survival benefit in a randomized controlled trial in patients with metastatic castration-resistant prostate cancer.
In Japan as well, based on the results of the Phase 2 study and TAX327 study in Japanese patients, it was approved in 2008 and has been adopted by the Japanese as the central standard treatment for CRPC as an anti-cancer chemotherapy for about 12 years. On the other hand, it has been safely and widely used in daily clinical use.
This symposium will outline clinical trials in Japan and overseas, the taxane anticancer drugs overseas, and the position of docetaxel in castration susceptibility.

キーワード

臓器別:前立腺・男性生殖器

前へ戻る